生长抑素类似物市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球生长抑素类似物市场价值为 72 亿美元，预计到 2034 年将以 7.2% 的复合年增长率成长，达到 143 亿美元。由于肢端肥大症、神经内分泌肿瘤和库欣氏症等荷尔蒙相关疾病的盛行率不断上升，市场持续获得成长动力。随着世界各地的医疗保健系统更加重视早期发现和个人化治疗，生长抑素类似物 (SSA) 正成为首选的治疗方案。它们调节过量荷尔蒙分泌的能力，加上药物配方和输送技术的不断创新，使它们非常适合慢性疾病的管理。

随着患者和医疗保健提供者对荷尔蒙失调的认识不断提高，对有效、微创和长效疗法的需求也在激增。此外，医学界向综合护理途径的转变正在鼓励更广泛地采用 SSA，并得到多个地区优惠的报销框架和监管批准的支持。药物传递的进步（例如长效注射剂）尤其透过提供更大的便利性和提高患者的依从性来推动药物的采用。市场也受益于针对更广泛治疗应用的临床研究的激增，从而为新的治疗领域打开了大门。

光是兰瑞肽一项，2024 年的收入就达到 39 亿美元。其快速增长反映了被诊断患有神经内分泌肿瘤的患者数量的增加。兰瑞肽的受欢迎程度源于其长效配方，这显着降低了给药频率——这对患者和医生来说都是一个有吸引力的因素。它能够透过更少的注射提供一致的治疗效果，从而提高治疗依从性。监管机构继续透过批准新的适应症来支持其扩大用途，这进一步加强了其临床相关性。随着越来越多的研究探索其在治疗其他荷尔蒙相关疾病方面的功效，兰瑞肽在不同的护理环境中继续获得应用。

以适应症划分，神经内分泌肿瘤在 2024 年占据最大的市场份额，为 46.8%。这种主导地位很大程度上得益于改进的诊断工具和成像技术，这些技术有助于早期和准确地检测。患者意识的提高和医生对针对性治疗的偏好导致 SSA 处方量显着增加。随着肿瘤学实践日益转向精准医疗，生长抑素类似物正成为长期肿瘤管理不可或缺的一部分。它们能够有效控制症状，并且具有良好的安全性，这增强了人们的采用率。

2024 年，美国生长抑素类似物市场产值达 30 亿美元。该国先进的医疗保健基础设施、广泛的诊断影像服务以及强大的保险覆盖范围都为这一强劲的市场地位做出了贡献。透过公共和私人保险管道获得经批准的 SSA 疗法可确保患者更好地获得治疗。罕见内分泌疾病的筛检计画正变得越来越普遍，有助于早期诊断和及时治疗。

主要参与者包括 Teva Pharmaceuticals、GlyTech、Ipsen Pharma、Sun Pharmaceutical、辉瑞、诺华、Debiopharm、Chiasma、Camurus、Crinetics Pharmaceuticals、Peptron 和 Dauntless Pharmaceuticals，他们正在大力投资长效注射剂和智慧输送系统，旨在提高依从性和疗效。这些公司优先考虑监管参与以简化审批流程，同时也专注于透过临床研究和研发合作扩大治疗适应症。战略许可、併购活动和全球扩张努力在加强其在生长抑素类似物领域的立足点方面发挥核心作用。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 荷尔蒙相关疾病盛行率不断上升
    • 生长抑素类似物药物和製剂的进展
    • 提高认识和诊断
    • 生长抑素类似物的应用不断扩大
  • 产业陷阱与挑战
    • 发展中地区的认知有限
    • 来自替代疗法的竞争
• 成长潜力分析
• 监管格局
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• 奥曲肽
• 兰瑞肽
• 帕瑞胜肽

第六章：市场估计与预测：按适应症，2021 - 2034 年

• 主要趋势
• 神经内分泌肿瘤（NET）
• 肢端肥大症
• 其他适应症

第七章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 肠外

第八章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 专科诊所
• 其他最终用途

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Camurus
• Chiasma
• Crinetics Pharmaceuticals
• Dauntless Pharmaceuticals
• Debiopharm
• GlyTech
• Ipsen Pharma
• Novartis
• Peptron
• Pfizer
• Sun Pharmaceutical
• Teva Pharmaceuticals

The Global Somatostatin Analogs Market was valued at USD 7.2 billion in 2024 and is estimated to grow at a CAGR of 7.2% to reach USD 14.3 billion by 2034. The market continues to gain momentum due to the rising prevalence of hormone-related conditions such as acromegaly, neuroendocrine tumors, and Cushing's disease. With healthcare systems worldwide placing greater emphasis on early detection and personalized treatments, somatostatin analogs (SSAs) are emerging as a preferred therapeutic solution. Their ability to regulate excess hormone secretion, coupled with ongoing innovations in drug formulation and delivery technologies, makes them highly suitable for chronic disease management.

As awareness about hormonal disorders increases among patients and healthcare providers, the demand for effective, minimally invasive, and long-acting therapies is surging. Moreover, the medical community's shift toward integrated care pathways is encouraging the wider adoption of SSAs, supported by favorable reimbursement frameworks and regulatory approvals across multiple regions. Advancements in drug delivery-such as long-acting injectables-are especially driving uptake by offering greater convenience and boosting patient compliance. The market is also benefiting from a surge in clinical research targeting broader therapeutic applications, thus opening doors to novel treatment areas.

The Lanreotide segment alone generated USD 3.9 billion in 2024. Its rapid growth reflects the increasing number of patients being diagnosed with neuroendocrine tumors. Lanreotide's popularity stems from its long-acting formulation, which significantly reduces the frequency of administration-an appealing factor for both patients and physicians. Its ability to deliver consistent therapeutic effects with fewer injections enhances treatment adherence. Regulatory authorities continue to support its expanded use by approving new indications, which further strengthens its clinical relevance. As more studies explore its efficacy in treating additional hormone-related conditions, lanreotide continues to gain ground across diverse care settings.

By indication, neuroendocrine tumors accounted for the largest market share at 46.8% in 2024. This dominance is largely driven by improved diagnostic tools and imaging technologies that facilitate early and accurate detection. The rise in patient awareness and physician preference for targeted treatments has led to a notable uptick in SSA prescriptions. With oncology practices increasingly turning to precision medicine, somatostatin analogs are becoming integral to long-term tumor management. Their ability to offer effective symptom control with a favorable safety profile is reinforcing their adoption.

The U.S. Somatostatin Analogs Market generated USD 3 billion in 2024. The country's advanced healthcare infrastructure, widespread access to diagnostic imaging, and strong insurance coverage have all contributed to this robust market presence. The availability of approved SSA therapies through both public and private insurance channels ensures better patient access. Screening programs for rare endocrine diseases are becoming more prevalent, aiding in early diagnosis and timely treatment.

Key players, including Teva Pharmaceuticals, GlyTech, Ipsen Pharma, Sun Pharmaceutical, Pfizer, Novartis, Debiopharm, Chiasma, Camurus, Crinetics Pharmaceuticals, Peptron, and Dauntless Pharmaceuticals, are heavily investing in long-acting injectables and smart delivery systems aimed at improving adherence and outcomes. These companies are prioritizing regulatory engagement to streamline approval processes while also focusing on expanding therapeutic indications through clinical research and R&D collaborations. Strategic licensing, M&A activities, and global expansion efforts are playing a central role in strengthening their foothold in the somatostatin analogs space.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hormone-related disorders
    • 3.2.1.2 Advancements in somatostatin analog drugs and formulations
    • 3.2.1.3 Increasing awareness and diagnosis
    • 3.2.1.4 Expanding application of somatostatin analogs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited awareness in developing regions
    • 3.2.2.2 Competition from alternative therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter’s analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Octreotide
• 5.3 Lanreotide
• 5.4 Pasireotide

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Neuroendocrine tumor (NET)
• 6.3 Acromegaly
• 6.4 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Camurus
• 10.2 Chiasma
• 10.3 Crinetics Pharmaceuticals
• 10.4 Dauntless Pharmaceuticals
• 10.5 Debiopharm
• 10.6 GlyTech
• 10.7 Ipsen Pharma
• 10.8 Novartis
• 10.9 Peptron
• 10.10 Pfizer
• 10.11 Sun Pharmaceutical
• 10.12 Teva Pharmaceuticals